慢性心力衰竭患者N端脑钠肽前体、脑钠肽与患者心脏超声参数及炎症因子的关系

目的:探讨慢性心力衰竭(CHF)患者N端脑钠肽前体(NT-proBNP)、脑钠肽(BNP)与患者心脏超声参数及炎症因子的关系。方法:选取2015年3月～2018年2月期间我院收治的CHF患者135例为研究组。根据纽约心脏病学协会(NYHA)心功能分级将研究组分为Ⅰ级组26例,Ⅱ级组34例,Ⅲ级组42例,IV级组33例。另选取同期于我院体检的健康志愿者30例为对照组。检测并比较对照组与研究组、不同NYHA心功能分级的血清标志物、炎症因子、心功能超声参数,采用Pearson相关性分析NT-proBNP、BNP与炎症因子、心功能超声参数的相关性。结果:研究组血清BNP、NT-proBNP、白介素-6(IL-6)、肿瘤坏死因子-α(TNF-α)、超敏C反应蛋白(hs-CRP)水平及左心室舒张末期内径(LVEDD)、左心室收缩末期内径(LVESD)均显著高于对照组,左心室射血分数(LVEF)则低于对照组(P0.05)。BNP、NT-proBNP、IL-6、TNF-α、hs-CRP水平及LVEDD、LVESD随心功能分级的升高而升高,LVEF随心功能分级的升高而降低(P0.05)。经Pearson相关性分析显示,CHF患者BNP、NT-proBNP与IL-6、TNF-α、hs-CRP、LVEDD、LVESD呈正相关,而与LVEF呈负相关(P0.05)。结论:血清NT-proBNP、BNP与CHF患者的心脏超声参数及炎症因子密切相关,可考虑将其作为临床诊断CHF的生物学指标。     

芪苈强心胶囊对慢性心力衰竭患者血清hs-CRP，TNF-α及IL-8水平的影响及其临床疗效

目的:探讨芪苈强心胶囊对慢性心力衰竭患者血清炎症因子水平的影响及其临床疗效。方法:选取2013年7月-2016年7月在我院接受治疗的慢性心力衰竭患者106例,随机分为对照组和研究组,每组53例。对照组患者采用常规抗心衰药物治疗,研究组患者在对照组基础上采用芪苈强心胶囊治疗。观察并比较两组患者治疗前后血清hs-CRP,TNF-α及IL-8水平、心功能指标及临床疗效。结果:研究组患者总有效率(81.1%)显著高于对照组(67.9%),差异具有统计学意义(P0.05);与治疗前比较,治疗后两组患者血清hs-CRP,TNF-α及IL-8水平均降低,差异均具有统计学意义(P0.05);与对照组比较,研究组患者治疗后血清hs-CRP,TNF-α及IL-8水平较低,差异具有统计学意义(P0.05);与治疗前比较,两组患者治疗后LVESD及LVEDD均降低,而LVEF均升高,差异均具有统计学意义(P0.05);与对照组比较,研究组患者治疗后LVESD及LVEDD较低,而LVEF较高,差异均具有统计学意义(P0.05)。结论:芪苈强心胶囊治疗慢性心力衰竭的临床效果显著,能够降低血清炎症因子水平,改善患者心功能指标,保护心肌细胞,值得临床推广及应用。     

贝那普利联合阿托伐他汀治疗慢性心力衰竭的临床疗效

目的:探讨贝那普利联合阿托伐他汀治疗慢性心力衰竭临床疗效及对患者血清炎症因子水平的影响。方法:收集我院2014年12月~2016年5月确诊为慢性心力衰竭的患者120例,随机分为观察组和对照组,各60例。对照组采用口服贝那普利治疗,观察组采用贝那普利联合阿托伐他汀治疗。观察并比较两组患者治疗前后左室收缩末期容积指数(LVESVI)、左室舒张末期容积指数(LVEDVI)、左心室舒张末期内径(LVEDD)、左心射血分数(LVEF)及血清NT-proBNP,hs-CRP,TNF-α,白介素-6(IL-6)及白介素-8(IL-8)水平的变化情况。结果:观察组有效率优于对照组,差异具有统计学意义(P0.05);治疗后,两组患者Pro-BNP、LVEDD、E/A均降低,且观察组低于对照组(P0.05);治疗后,两组患者LVEF升高,且观察组高于对照组(P0.05);两组患者治疗后血清hs-CRP,TNF-α,IL-6及IL-8水平均降低,且观察组低于对照组(P0.05)。结论:贝那普利联合阿托伐他汀治疗对慢性心力衰竭患者进行治疗,疗效显著,患者炎症反应小,是一种安全有效的治疗方法。     

慢性心力衰竭患者外周血miR-148a表达水平与炎症因子、心功能和心室重构的关系

摘要 目的：探讨慢性心力衰竭（CHF）患者血清miR-148a表达水平与炎症因子、心功能和心室重构的关系。方法：选择2017年1月~2019年1月在我院就诊的CHF患者136例,按照美国纽约心脏病学会（NYHA）心功能分级将患者分为Ⅱ级57例、Ⅲ级43例和Ⅳ级36例。实时荧光定量PCR检测血清miR-148a的表达,血清中白细胞介素-1（IL-1）、白细胞介素6（IL-6）和肿瘤坏死因子-α（TNF-α）的含量用酶联免疫吸附试验检测,使用超声心动图检测心功能和心室重构指标,主要包括左室舒张末期内径（LVEDD）、舒张末室间隔厚度（IVSD）、舒张末左室后壁厚度（PWD）、左室质量指数（LVMI）、左室射血分数（LVEF）和左室重构指数（LVRI）,采用Pearson积矩相关系数分析血清miR-148a表达水平与血清炎症因子、超声心动图指标之间的相关性。结果：CHF患者血清miR-148a表达量随心功能分级升高而降低（P均<0.05）。炎症因子（IL-1、IL-6和TNF-α）水平和LVEDD、PWD、IVSD、LVMI随心功能分级升高而升高, LVRI和LVEF随心功能分级升高而降低（P<0.05）。血清miR-148a表达量与炎症因子、IVSD、PWD和LVMI呈负相关（P<0.05）;与LVEF和LVRI呈正相关（P<0.05）。结论：血清miR-148a表达量与CHF患者血清炎症因子水平、心功能及心室重构关系密切,提示检测血清miR-148a有助于反映CHF患者病情的严重程度。     

miR-125b在急性加重期慢性阻塞性肺疾病患者血浆中的表达及与肺功能和炎症细胞因子的关系

目的:探讨微小RNA-125b(miR-125b)在急性加重期慢性阻塞性肺疾病(COPD)患者血浆中的表达及其与肺功能、炎症细胞因子的关系。方法:选择2016年11月至2019年1月应急总医院收治的69例急性加重期COPD患者作为急性加重组,并于同期随机选取58例稳定期COPD患者作为稳定组和50例健康体检者作为对照组。采用实时荧光定量PCR法检测各组血浆miR-125b表达水平;采用肺功能检测仪测定肺功能,包括用力肺活量(FVC)、第1秒用力呼气量(FEV_1)、FEV_1/FVC;采用酶联免疫吸附法测定血清炎症细胞因子,包括白细胞介素-6(IL-6)、白细胞介素-8(IL-8)、高敏C反应蛋白(hs-CRP)、肿瘤坏死因子-α(TNF-α)。结果:急性加重组血浆miR-125b表达水平高于稳定组和对照组,差异有统计学意义(P0.05)。急性加重组、稳定组肺功能指标FVC、FEV_1、FEV_1/FVC低于对照组,且急性加重组低于稳定组,差异有统计学意义(P0.05)。急性加重组、稳定组血清炎症细胞因子IL-6、IL-8、hs-CRP、TNF-α水平高于对照组,且急性加重组高于稳定组,差异有统计学意义(P0.05)。Pearson相关分析结果显示,急性加重期COPD患者血浆miR-125表达水平与FVC、FEV_1、FEV_1/FVC呈负相关(P0.05),与IL-6、IL-8、hs-CRP、TNF-α呈正相关(P0.05)。结论:miR-125b在急性加重期COPD患者血浆中异常表达,并与肺功能及炎症细胞因子密切相关,可作为临床辅助诊断及评估患者病情严重程度的参考指标。     

稳心颗粒联合普罗帕酮用于心律失常的疗效研究及对血清hs-CRP、TNF-α、IL-6与心功能的影响

目的:探讨稳心颗粒联合普罗帕酮治疗心律失常的临床疗效研究及对血清高敏C反应蛋白(hs-CRP)、肿瘤坏死因子(TNF)-α、白介素(IL)-6水平与心功能的影响。方法:选择2014年7月至2016年10月我院接诊的96例心律失常患者,通过随机数表法分为观察组(n=48)和对照组(n=48)。对照组给予普罗帕酮治疗,观察组在此基础上,联用稳心颗粒。治疗4周后,比较两组血清hs-CRP、TNF-α、IL-6水平、心功能、临床疗效以及不良反应的发生情况。结果:治疗后,观察组临床疗效总有效率明显高于对照组(P0.05);血清hs-CRP、TNF-α、IL-6水平均明显低于对照组(P0.05);观察组左室舒张末期内径(LVEDD)、左室收缩末期内径(LVESD)显著低于对照组,左室射血分数(LVEF)明显高于对照组(P0.05);观察组不良反应发生率明显低于对照组(P0.05)。结论:稳心颗粒联合普罗帕酮治疗心律失常的效果显著,可有效改善患者心功能,安全性高,可能与其降低血清hs-CRP、TNF-α、IL-6表达有关。     

左西孟旦联合螺内酯对慢性心力衰竭患者血清炎症因子水平及心室重构的影响研究

目的:研究左西孟旦联合螺内酯对慢性心力衰竭患者血清炎症因子水平及心室重构的影响。方法:选择2015年1月-2017年12月我院干部病房收治的88例慢性心力衰竭患者,将其随机分为两组。对照组单纯口服螺内酯,每次20 mg,每天1次;观察组联合采取左西孟旦治疗。观察和比较两组治疗前后的心功能指标(左心室舒张期末内径、6 min步行试验、左心室射血分数以及左心室收缩期末内径),血清肿瘤坏死因子-α(tumor necrosis factor-α,TNF-α)、白介素-6 (interleukin-6,IL-6)、高敏C-反应蛋白(high sensitivity C-reactive protein,hs-CRP)、N端脑钠肽前体(N-terminal pro-brain natriuretic peptide,NT-proBNP)水平的变化情况。结果:治疗后,观察组的有效率明显高于对照组(90.91%vs. 72.73%,P0.05);两组治疗后左心室舒张期末内径、左心室收缩期末内径、血清hs-CRP、TNF-α、IL-6和NT-proBNP水平均较治疗前显著降低,而左心室射血分数及6 min步行试验均较治疗前明显增加(P0.05),且观察组左心室舒张期末内径、左心室收缩期末内径、血清hs-CRP、TNF-α、IL-6和NT-proBNP水平明显低于对照组,左心室射血分数及6 min步行试验显著高于对照组(P0.05)。结论:左西孟旦联合螺内酯治疗慢性心力衰竭患者可能显著提高其临床疗效,可能与其有效改善患者的心功能以及心室重构、减轻机体炎症反应有关。     

扩张型心肌病慢性心力衰竭患者血浆脑利钠肽水平的临床意义

目的:探究扩张型心肌病慢性心力衰竭患者血浆脑利钠肽水平的临床意义。方法:收集2012年3月至2016年3月我院收治的90例扩张型心肌病慢性心力衰竭患者,将患者按照NYHA心功能分级分为A组(II级)20例、B组(III级)38例、C组(IV级)32例。比较各组患者的血浆脑力钠肽(BNP)以及超声心动图相关指标,包括左心室射血分数(LVEF)、左心房内径(LA)、左室舒张末期内径(LVEDD)以及左室收缩末期内径(LVESD),分析血浆BNP与NYHA分级和超声心动图相关指标的相关性,以及比较血浆BNP和LVEF在慢性心力衰竭病情程度中的能力。结果:C组患者的血浆BNP浓度显著高于A组和B组(P0.05),而B组患者的血浆BNP浓度显著高于A组,比较差异具有统计学意义(P0.05)。心脏超声检测发现,C组患者的LA显著高于A组(P0.05),而LVEF、LVEDD及LVESD比较差异无统计学意义(P0.05)。血浆BNP与NYHA分级呈正相关关系,但与LVEDD、LVESD、LVEF、LA无明显相关关系(P0.05)。血浆BNP对评价心力衰竭患者病情程度呈现出较强的能力(受试者工作特征曲线下面积=0.902,P0.001)。血浆BNP=523.5 pg/mL为中重度心力衰竭患者的诊断最佳值。LVEF对评价心力衰竭患者病情程度无明显能力(受试者工作特征曲线下面积=0.392,P=0.276)。结论:血浆BNP浓度对扩张型心肌病慢性心力衰竭患者的诊断、筛查以及心功能分级具有重要的临床意义。     

不同剂量阿托伐他汀对冠心病患者心功能、血脂及血清TNF-α、ANF水平的影响

目的:探讨不同剂量阿托伐他汀对冠心病患者心功能、血脂及血清肿瘤坏死因子-α(TNF-α)、心钠素(ANF)水平的影响。方法:选取2016年1月到2017年1月在我院接受治疗的冠心病患者86例,根据随机数字表法将患者分为观察组和对照组,各43例,对照组给予10 mg剂量的阿托伐他汀进行治疗,观察组给予20 mg剂量的阿托伐他汀进行治疗,两组均治疗6个月。比较两组患者治疗前后的左心室舒张末期内径(LVEDD)、左心室射血分数(LVEF)、左心房前后径(LAD)、总胆固醇(TC)、甘油三酯(TG)、高密度脂蛋白胆固醇(HDL-C)、低密度脂蛋白胆固醇(LDL-C)、TNF-α、ANF水平。对所有患者进行1年的随访,比较患者出现心肌梗死、心律失常、心源性死亡等心血管事件的情况。结果:治疗后两组的LVEDD、LAD、TC、TG、LDL-C、TNF-α、ANF均显著降低,LVEF、HDL-C显著升高(P0.05),治疗后观察组的LVEDD、LAD、TC、TG、LDL-C、TNF-α、ANF低于对照组,LVEF高于对照组(P0.05)。两组的心血管事件发生率比较无统计学差异(P0.05)。结论:两种剂量的阿托伐他汀均能有效的改善冠心病患者的心功能和血脂,降低患者体内的炎症反应,但20 mg剂量的阿托伐他汀效果更佳。     

氯吡格雷联合阿司匹林对冠心病心绞痛患者血清hs-CRP,TNF-α及IL-6水平的影响

目的:探讨氯吡格雷与阿司匹林对冠心病心绞痛患者血清炎症因子水平的影响及其临床疗效。方法:选择2014年3月-2016年3月在我院确诊为冠心病心绞痛患者69例作为研究对象,根据治疗方法不同,将患者随机分成研究组(39例)和对照组(30例)。对照组患者采用阿司匹林治疗,研究组患者在此基础上联合使用氯吡格雷治疗。观察并比较两组患者治疗前后血清高敏C-反应蛋白(high-sensitivity C-reactive protein,hs-CRP)、肿瘤坏死因子-α(tumor necrosis factor-α,TNF-α)及白细胞介素-6(interleukin-6,IL-6)水平的变化情况,以及临床疗效。结果:治疗前两组患者血清hs-CRP,IL-6及TNF-α水平比较,差异无统计学意义(P0.05);治疗后两组患者血清hs-CRP,IL-6及TNF-α水平均低于治疗前,且研究组低于对照组,差异具有统计学意义(P0.05)。研究组患者临床总有效率(94.7%)高于对照组(88.9%),差异具有统计学意义(P0.05)。结论:氯吡格雷联合阿司匹林治疗冠心病心绞痛的临床效果显著,能够降低患者血清hs-CRP,IL-6及TNF-α炎症因子水平,值得临床推广应用。     

冠心病患者静息心率与血小板活性相关研究

目的:探讨冠心病患者静息心率与血小板活性的相关研究。方法:选择2013年1月至2014年9月于我院住院患者474例,按静息心率快慢分为三组,心率70 bmp为第一组(Q1)150例,心率位于70~85 bmp为第二组(Q2)265例,心率85 bmp为第三组(Q3)59例,三组患者均于病情稳定时行血栓弹力图(TEG)中MA值检测,同时随访3个月,观察和比较三组患者MA值变化及预后。结果:三组患者MA值分别为61.16±7.29 mm、62.02±7.46 mm、65.32±6.56 mm,第三组患者MA值与第一组或第二组患者MA值比较差异均存在统计学意义(P0.05),通过血栓弹力图检测三组经花生四烯酸(AA)途径的血小板抑制率和经二磷酸腺苷(ADP)途径的血小板抑制率发现,静息心率高低与抗血小板药物作用疗效无相关关系(P0.05)。随访3个月,三组患者心绞痛、再住院、脑血管病及死亡的总发生率分别为28%、28.68%、40.67%。结论:冠心病患者静息心率越快,MA值越大即血小板活性越高,静息心率的高低与抗血小板药物作用疗效无关。     

Implantation of Total Artificial Heart in Congenital Heart Disease

In patients with end-stage heart failure (HF), a total artificial heart (TAH) may be implanted as a bridge to cardiac transplant. However, in congenital heart disease (CHD), the malformed heart presents a challenge to TAH implantation. In the case presented here, a 17 year-old patient with congenital transposition of the great arteries (CCTGA) experienced progressively worsening HF due to his congenital condition. He was hospitalized multiple times and received an implantable cardioverter defibrillator (ICD). However, his condition soon deteriorated to end-stage HF with multisystem organ failure. Due to the patient''s grave clinical condition and the presence of complex cardiac lesions, the decision was made to proceed with a TAH. The abnormal arrangement of the patient''s ventricles and great arteries required modifications to the TAH during implantation.With the TAH in place, the patient was able to return home and regain strength and physical well-being while awaiting a donor heart. He was successfully bridged to heart transplantation 5 months after receiving the device. This report highlights the TAH is feasible even in patients with structurally abnormal hearts, with technical modification.     

Transfer of Heart Rate Feedback Training to Reduce Heart Rate Response to Laboratory Tasks

To examine whether transfer of heart rate (HR) feedback training to tasks not used during training could be improved by using multiple tasks during training, a modified multiple baseline across tasks, single subject design study was conducted using six high HR-reactive young adults. Participants received HR feedback training during the presentation of a videogame, and transfer of training was assessed to a mental arithmetic challenge and handgrip task. Transfer of training was next assessed following training with the mental arithmetic challenge and handgrip task. HR responses to each training task with no HR feedback were assessed during a pre-treatment session, an immediate post-training period following training on each task, a short delay (1–2 days) post-training session, and a long delay (1–2 weeks) post-training session. HR response to a novel speech task was assessed at pre-treatment and during short delay and long delay post-training sessions. Results revealed that participants reduced HR during training and generally maintained this reduction in HR during the immediate post-training assessment when HR feedback was not present. Participants were not able to reduce HR responses to tasks during short delay and long delay post-training sessions, and they were unable to transfer HR reduction skills to the speech task. Transfer of HR feedback training to new tasks was limited in nature and efforts to train across multiple stressors did not appear to improve transfer of training.     

静息心率与慢性心力衰竭患者血清NT-proBNP的相关性分析

目的:探讨入院时静息心率与慢性心力衰竭患者血清N末端B型钠尿肽原(NT-pro BNP)相关性。方法:选取我院收治的242例慢性心力衰竭患者为研究对象,按静息心率将患者分为Ⅰ组(心率70次/min),Ⅱ组(心率:70%~90次/min),Ⅲ组(心率90次/min);测量患者入院时血清NT-pro BNP水平,按照其中位数分为两组:NT-pro BNP2087.63 pg/m L组和NT-pro BNP≥2087.63 pg/m L,比较各组相关指标的差异。用多元线性回归分析静息心率与血清NT-pro BNP的关系。结果:三组在收缩压、心功能分级、左室射血分数(LVEF)、左室舒张末内径(LVEDD)、空腹血糖(FPG)比较具有统计学差异(P0.05),与Ⅰ组及Ⅱ组比较,Ⅲ组患者收缩压、LVEDD、FPG,NYHA心功能分级Ⅲ~Ⅳ比例较高、LVEF偏低;三组在血清NT-pro BNP比较亦存在显著的统计学差异(P0.05),Ⅲ组高于Ⅰ组及Ⅱ组、Ⅱ组高于Ⅰ组;与NT-pro BNP2087.63 pg/m L组比较,NT-pro BNP≥2087.63 pg/m L组静息心率偏快,且患者中90(次/min)的比例较高(P0.05)。静息心率与与NT-pro BNP呈正相关(r=0.281,P=0.035);静息心率是影响NT-pro BNP水平的独立危险因素。结论:静息心率水平与慢性心力衰竭患者血清NT-pro BNP水平密切相关。     

An Examination of the Relationship Between Resting Heart Rate Variability and Heart Rate Reactivity to a Mental Arithmetic Stressor

Resting heart rate variability can be an index of sympathetic or parasympathetic dominance, according to the frequency of the variability studied. Sympathetic dominance of this system has been linked to increased risk of cardiovascular disease (CVD). Similarly, rapid and dramatic increases in heart rate reactivity to a stressor task have also been suggested as indicating increased risk of CVD via atherogenesis. Although both of these variables have been related to the development of cardiovascular disease, and both may be related to increased sympathetic activity or parasympathetic withdrawal, most research studies have tended to focus on either variable independently of the other. In order to investigate whether these two indices of stressor reactivity were related in relatively young and healthy subjects, resting heart rate variability data were collected from 80 volunteers for 20 minutes. In addition, heart rate reactivity data were collected during a 2-minute mental arithmetic stressor, which has been previously shown to induce significant increases in heart rate. After classifying subjects according to whether their heart rate variability data were above or below the mean for their gender, heart rate reactivity data were examined via MANOVA to detect significant differences between subject groups. Females showed significant effects, and males showed nonsignificant trends, but these two sets of data were in different directions, suggesting that gender may be a confounding factor in the relationship between heart rate reactivity and heart rate variability.     

Heart glycogen content and isoprenaline-induced myocardial lesions

The role of glycogen content in the heart for the development of isoprenaline-induced myocardial lesions (IML) was studied in Wistar rats and in two inbred rat strains: In IR rats (resistant to the development of IML) and in IS rats (sensitive to IML development).Glycogen content in the heart can be dramatically lowered or increased by various interventions. IML develop during the period of very low heart glycogen content (about 0.6 mg.g^–1) induced by isoprenaline administration. In animals with increased resistance to IML, either due to genetic factors or induced by isoprenaline pretreatment a high glycogen content in the heart is found (up to 7.5 mg.g^–1).The increase of resistance to IML development and increased glycogen content induced by isoprenaline pretreatment were accompanied by lower basal or ISO-, guanylylimidodiphosphate- (Gpp/NH/p) and forskolin-stimulated activities of adenylyl cyclase. On the other hand, these parameters did not differ between IR and IS rats in spite of the presence of significant differences in the resistance to the development of IML and in heart glycogen content in these two rats strains.These results suggest that genetically determined differences between two inbred rat strains in the resistance of the heart to the development of IML and in the heart glycogen content are caused by factors which are independent of the receptor-adenylyl cyclase complex and are therefore different from those involved in the increase of resistance and glycogen content due to isoprenaline pretreatment.     

蝮蛇抗栓酶伍用刺五加对冠心病心率变异性的影响

目的探讨蝮蛇抗栓酶伍用刺五加对冠心病心率异性的影响。方法观察蝮蛇抗栓酶伍用刺五加对冠心病变异性的影响,并与对照组对比。结果治疗组ＳＤＮＮ、ＨＦ、ＬＦ／ＨＦ改变较对照组有显著差异性（Ｐ＜０．０１）。结论该方法能显著提高冠心病患者的心率变异性,对冠心病心源性猝死的预防有着重要意义。     

心脏原基的起源和发育

有关心脏前体位置的报道并不一致.主要对心脏前体的研究,包括命运图、细胞移植和培养及在心脏发育过程中起作用的组织相互作用、信号分子及基因调控机制几个方面进行了综述.另外,对最近报道的次生心脏形成区也进行了介绍.早期心脏发育的调控事件的确定可为新的治疗心肌症的途径提供必要的基础.     

同型半胱氨酸与冠心病

随着社会的进步以及人类生活水平的提高,冠心痛的发病率也逐年提高,目前已经成为全球死亡率最高的疾病之一,同时医学水平的不断发展也使得人们对冠心病有了更进一步的研究.近年来同型半胱氨酸越来越受到人们的关注,众多研究表明,高同型半胱氨酸血症是冠心痛的独立危险因子,可以影响冠心病的严重程度及预后.但是迄今为止,同型半胱氨酸在冠心病发病中的确切机制尚不完全明确,认为主要与血管内皮损伤、血管平滑肌细胞增殖凋亡、破坏凝血纤溶系统、影响糖、蛋白质、脂质代谢等方面有关.针对高同型半胱氨酸血症的治疗,对于改善冠心病患者的预后有一定疗效.因此,本文就同型半胱氨酸冠心痛的关系作一综述,从而为临床更好的防治冠心痛提供相关的资料.